EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA

Marina Danilenko iD, Sharanya Nath iD, Jack Baines iD, Freya Gordon, Swathi Merugu, Lisa M Allinson iD, Aaron Potts, Bethany Collins, Angharad Goodman iD, Samuel E Kidman, Ciaron McAnulty, David Jamieson iD und 1 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26199466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marina Danilenko und 12 weiteren Autor:innen. Beteiligte Einrichtung: Wolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Herschel Building, New…. Hauptthemen laut MEDLINE: Neuroblastoma, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Blood Cancer UK, Little Princess Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroblastoma (NB) is an aggressive childhood cancer requiring intensive multimodal therapies in high-risk (HRNB) patients. Currently, invasive surgical biopsies are required to classify NB risk group and assign treatment based on the tumour genetic profile. Circulating tumour DNA (ctDNA) obtained from blood samples can be used to identify tumour biomarkers. Here we applied targeted next-generation sequencing (tNGS) using a panel of 42 genes to analyse 32 NB ctDNA samples for the presence of single-nucleotide variants and copy number changes from 28 patients in all NB risk groups. In two additional ctDNA samples, droplet digital PCR was used to detect hotspot ALK variants. Pathogenic mutations with a variant allele frequency (VAF) > 1% were identified in 13/32 (41%) ctDNA samples. ALK and PTPN11 were the most frequent, each being detected in 4/32 (13%) samples, together with oncogene amplifications. Targeted NGS of ctDNA detected actionable variants, including those absent in the diagnostic primary tumour due to spatial and temporal heterogeneity. Our findings confirm the usefulness of ctDNA in detecting genetic abnormalities in NB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaCirculating Tumor DNABiomarkers, TumorHumansHigh-Throughput Nucleotide SequencingMaleFemaleMutationDNA Copy Number VariationsChild, PreschoolInfantPolymorphism, Single NucleotideAnaplastic Lymphoma KinaseChildProtein Tyrosine Phosphatase, Non-Receptor Type 11Gene Frequency

Stichwörter der Autor:innen

circulating tumour DNAddPCRliquid biopsyneuroblastomanext-generation sequencingpaediatric cancer

Substanzen

Circulating Tumor DNABiomarkers, TumorAnaplastic Lymphoma KinaseALK protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, human

Autor:innen und Institutionen

  • Wolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Herschel Building, Newcastle upon Tyne NE1 7RU, UK.
  • Newcastle Genetics Lab., Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4EP, UK.
  • Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53726, USA.
  • Childhood Brain Tumour Research Group, Developmental Biology and Cancer, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
  • The Immune Monitoring Facility, Ludwig Centre for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Paul O'Gorman Building, Newcastle upon Tyne NE2 4HH, UK.

ORCID-Profile: Marina Danilenko, Sharanya Nath, Jack Baines, Lisa M Allinson, Angharad Goodman, David Jamieson, Deborah A Tweddle

Förderung

  • Cancer Research UK
  • Blood Cancer UK
  • Little Princess Trust
  • NCI NIH HHS
  • Sir Bobby Robson Foundation, Little Princess Trust
  • Children’s Cancer North, a CR UK Centre
  • Action Medical Research/Great Ormond Street Hospital Charity
  • Horizon Europe-Mission Cancer THRIVE

Zitieren

APA

Danilenko, M., Nath, S., Baines, J., Gordon, F., Merugu, S., Allinson, L. M., Potts, A., Collins, B., Goodman, A., Kidman, S. E., McAnulty, C., Jamieson, D., & Tweddle, D. A. (2025). Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199466

Vancouver

Danilenko M, Nath S, Baines J, Gordon F, Merugu S, Allinson LM, et al. Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199466

BibTeX
@article{Danilenko2025,
  author = {Danilenko, Marina and Nath, Sharanya and Baines, Jack and Gordon, Freya and Merugu, Swathi and Allinson, Lisa M and Potts, Aaron and Collins, Bethany and Goodman, Angharad and Kidman, Samuel E and McAnulty, Ciaron and Jamieson, David and Tweddle, Deborah A},
  title = {Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26199466}
}
Kostenlos starten →